Presbyopia is a common age-related issue, with an estimated 1.09 billion to 1.80 billion people globally affected. The condition can significantly diminish the quality of life, making everyday tasks challenging. PresVu promises to alleviate this burden by improving near vision within just 15 minutes of application. Additionally, the eye drops provide an added benefit by lubricating the eyes, thanks to its advanced dynamic buffer technology that adapts quickly to the pH of tears, ensuring prolonged effectiveness and protection.

Entod Pharmaceuticals, led by CEO Nikhil K Masurkar, has applied for a patent on the formulation and process of PresVu, highlighting the innovation behind the product. Masurkar emphasized that the approval by DCGI is a crucial milestone in the company’s mission to revolutionize eye care in India. He stated that PresVu is more than just a product; it is a solution that aims to enhance the lives of millions by improving their vision.

Dr. Aditya Sethi praised PresVu as a significant breakthrough, noting its ability to improve near vision quickly and effectively, thus enhancing the quality of life for those with presbyopia. Dr. Dhananjay Bakhle echoed this sentiment, describing the approval of PresVu as a promising achievement in ophthalmology, offering a convenient, non-invasive option for presbyopia patients.

Presbyopia is a common age-related issue, with an estimated 1.09 billion to 1.80 billion people globally affected. The condition can significantly diminish the quality of life, making everyday tasks challenging. PresVu promises to alleviate this burden by improving near vision within just 15 minutes of application. Additionally, the eye drops provide an added benefit by lubricating the eyes, thanks to its advanced dynamic buffer technology that adapts quickly to the pH of tears, ensuring prolonged effectiveness and protection.

Entod Pharmaceuticals, led by CEO Nikhil K Masurkar, has applied for a patent on the formulation and process of PresVu, highlighting the innovation behind the product. Masurkar emphasized that the approval by DCGI is a crucial milestone in the company’s mission to revolutionize eye care in India. He stated that PresVu is more than just a product; it is a solution that aims to enhance the lives of millions by improving their vision.

Dr. Aditya Sethi praised PresVu as a significant breakthrough, noting its ability to improve near vision quickly and effectively, thus enhancing the quality of life for those with presbyopia. Dr. Dhananjay Bakhle echoed this sentiment, describing the approval of PresVu as a promising achievement in ophthalmology, offering a convenient, non-invasive option for presbyopia patients.